Re: BIOD's insulin variant
It's not quite fair to say that it was only stat sig by excluding India, as that was the Type I trial only (and type II is obviously the "market").
OTOH, I suspect the real issue is that it was stat sig inferior to Humulin, despite being stat sig non-inferior (yes, I think I said that right). How common is that?
It's probably not a good idea to have an also ran in this market.
Market Data 
Markets 
AI
